# First-line Treatment of PCNSL With the Combination of Orelabrutinib, Rituximab, and Methotrexate (ORM Regimen)

> **NCT06454266** · PHASE2 · COMPLETED · sponsor: **Ningbo No. 1 Hospital** · enrollment: 22 (actual)

## Conditions studied

- Primary Central Nervous System Lymphoma

## Interventions

- **DRUG:** ORM regimen

## Key facts

- **NCT ID:** NCT06454266
- **Lead sponsor:** Ningbo No. 1 Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-28
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-07-25
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2024-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06454266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06454266, "First-line Treatment of PCNSL With the Combination of Orelabrutinib, Rituximab, and Methotrexate (ORM Regimen)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06454266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*